Answers are grounded in this paper and cite their sources.
Randomized trial evaluates treatment benefit of lecanemab in patients with low amyloid levels, suggesting potential time savings in care.
To evaluate the benefit of continued treatment with lecanemab using a more clinically meaningful metric than the continuous outcome measures often used as primary endpoints in clinical trials, especially in a group with low baseline amyloid.
No takes yet. Share an insight, caveat, or question.
Dickson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: